New Kite Clinical Research and Real-World Evidence for Yescarta® Demonstrate Benefit From Earlier Lines of Treatment
SANTA MONICA, Calif.--(BUSINESS WIRE)--Kite, a Gilead Company (Nasdaq: GILD), today announced results from three new analyses for Yescarta® (axicabtagene ciloleucel) in relapsed/refractory (R/R) la...
Gilead Sciences, Inc. (GILD) Goldman Sachs 45th Annual Global Healthcare Conference (Transcript)
Gilead Sciences, Inc. (NASDAQ:GILD ) Goldman Sachs 45th Annual Global Healthcare Conference June 12, 2024 1:20 PM ET Company Participants Daniel O'Day - Chairman and Chief Executive Officer Confere...
3 Stocks With Mouthwatering Dividends You Can Buy Right Now
Gilead Sciences is a safe, reliable dividend stock. Organon pays a high dividend yield and has been a big winner for investors this year.
Gilead (GILD), RCUS Announce Data From Colorectal Cancer Study
Gilead (GILD) and partner Arcus Biosciences (RCUS) present data from metastatic colorectal cancer and gastrointestinal cancer study.
Gilead's (GILD) Urothelial Cancer Study Did Not Meet Its Primary Goal
Gilead Sciences, Inc.'s (GILD) confirmatory TROPiCS-04 study on Trodelvy in locally advanced or metastatic urothelial cancer fails to achieve its primary endpoint.
Gilead's Trodelvy extends lung cancer survival by just 1.3 months in trial
Gilead Sciences' Trodelvy improved survival by 1.3 months more than chemotherapy in previously treated patients with advanced lung cancer in a late-stage trial, a difference that was not statistica...
EVOKE-01 Study Results in Metastatic NSCLC to Be Presented at an Oral Session at ASCO 2024
FOSTER CITY, Calif.--(BUSINESS WIRE)--Gilead Sciences, Inc. (Nasdaq: GILD) today announced detailed results from the Phase 3 EVOKE-01 study that will be presented during an oral session (Abstract #...
Gilead's Trodelvy fails to meet main goal in late-stage study
Gilead Sciences said on Thursday its drug Trodelvy, tested in patients with bladder cancer who previously received chemotherapy, did not meet the main goal of a late-stage study.
Gilead Provides Update on Phase 3 TROPiCS-04 Study
FOSTER CITY, Calif.--(BUSINESS WIRE)--Gilead Sciences, Inc. (Nasdaq: GILD) today announced topline results from the confirmatory Phase 3 TROPiCS-04 study in locally advanced or metastatic urothelia...
Cancer Biotech Stocks Are on the Move Ahead of a Big Event. What to Know.
The American Society of Clinical Oncology is set to gather on May 31 in Chicago for its annual meeting. Companies such as GSK, Moderna, BioNTech, Gilead, and many others will reporting their progress.
Gilead (GILD) Announces Positive Interim Results on PBC Drug
Gilead Sciences (GILD) experimental candidate, seladelpar, demonstrates significant improvements in liver disease progression and reduced itching in primary biliary cholangitis study.
Gilead (GILD) Q1 Loss Narrower Than Expected, Sales Beat
Gilead (GILD) reports narrower-than-expected loss in the first quarter. Its sales beat estimates on higher HIV, Oncology and Liver Disease sales.
Gilead (GILD) Reports Q1 Earnings: What Key Metrics Have to Say
Although the revenue and EPS for Gilead (GILD) give a sense of how its business performed in the quarter ended March 2024, it might be worth considering how some key metrics compare with Wall Stree...
Gilead Sciences (GILD) Reports Q1 Loss, Tops Revenue Estimates
Gilead Sciences (GILD) came out with a quarterly loss of $1.32 per share versus the Zacks Consensus Estimate of a loss of $1.49. This compares to earnings of $1.37 per share a year ago.
Gilead Beats Earnings Expectations After Rocky Quarter
The biotech reported a loss for the quarter of $1.32 per share, better than the FactSet consensus estimate of a loss of $1.49 per share.
Related Companies